Pluristem Therapeutics Inc (PSTI)

[Auto1]

Limited Resources = Limited Clinical Trials

PLX-11, I get that, however, these other indications are also HUGE $B markets and the results seen with PLX were Remarkable. Aplastic Anemia for one...

Wouldn't an alternative reason be that Leadership is/was incapable of getting the data in front of the most influential thought leaders, published in the journals with the highest 'impact factors', getting the results on CNBC etal., where the investor community can be educated, can buy the stock and fund the research? Seemingly, with success, the ability to fund ANY future research and development.

It makes sense for seasoned companies to 'pass' on some indications Vs. others, but with NOTHING, one would think at least 1 ODD would be likely approved through an accelerated review and cooperation with the FDA.

That's how others have become successful, getting the data in front of the investment banks & analysts that talk to investors. Selling the Story... This, IMO, is where CEO's with decades of biopharma experience have driven their companies.

We are talking Billion dollar indications here. Besides, if the 'market' is not large, all the more reason to have the ODD and be able to charge a massive premium for every dose, thus justifying the cost of development and a return for shareholders. Aplastic Anemia & Bruegers Disease for two...


Alexion in PNH is an example. A 12 patient study went into the NEJM and the rest is history. Just an alternative perspective.